This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Apollo Endosurgery Dirección

Dirección controles de criterios 3/4

Información clave

Chas McKhann

Chief Executive Officer (CEO)

US$2.8m

Compensación total

Porcentaje del salario del CEO	19.8%
Permanencia del CEO	2.1yrs
Participación del CEO	0.4%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	5.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chas McKhann en comparación con los beneficios de Apollo Endosurgery?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	US$3m	US$550k	-US$40m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$9m	US$375k	-US$25m

Compensación vs. Mercado: Chas's total compensation ($USD2.78M) is above average for companies of similar size in the German market ($USD886.27K).

Compensación vs. Ingresos: Chas's compensation has been consistent with company performance over the past year.

CEO

Chas McKhann (53 yo)

2.1yrs

Permanencia

US$2,780,544

Compensación

Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% $ 2.1m
Jeffrey Black	CFO, Secretary & Treasurer	1.7yrs	US$1.34m	0.18% $ 951.6k
John Molesphini	Executive Vice President of Operations	5yrs	US$662.23k	0.079% $ 422.7k
Sergey Kantsevoy	Co-Founder and Innovation Partner	no data	sin datos	sin datos
Anthony Kalloo	Co-Founder and Innovation Partner	no data	sin datos	sin datos
Robert Hawes	Co-Founder and Innovation Partner	no data	sin datos	sin datos
Peter Cotton	Co-Founder and Innovation Partner	18.3yrs	sin datos	sin datos
Christopher Gostout	Co-Founder & Chief Medical Officer	no data	US$1.16m	0.062% $ 331.3k
Sydney Chung	Co-Founder and Innovation Partner	no data	sin datos	sin datos
Pankaj Pasricha	Co-Founder	18.3yrs	sin datos	sin datos
John Gillings	Investor Relations Manager	no data	sin datos	sin datos
Brian Szymczak	Vice President of Legal & Compliance	3.6yrs	sin datos	sin datos

4.3yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: HQ8F's management team is considered experienced (4.3 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% $ 2.1m
John Barr	Independent Chairman of the Board	4.1yrs	US$193.24k	0.051% $ 273.8k
Julie Shimer	Independent Director	4.9yrs	US$164.49k	0.038% $ 199.9k
Richard McGaughy	Independent Director	11.3yrs	US$165.15k	sin datos
William McClellan	Independent Director	8.9yrs	US$169.49k	0.047% $ 247.9k
Adrian Park	Member of Scientific Advisory Board	no data	sin datos	sin datos
Mark Talamini	Member of Scientific Advisory Board	no data	sin datos	sin datos
Santiago Horgan	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jay Redan	Member of Scientific Advisory Board	no data	sin datos	sin datos
Steve McCarus	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeffrey Marks	Member of Scientific Advisory Board	no data	sin datos	sin datos
David Pacitti	Independent Director	5.4yrs	US$159.70k	0.0067% $ 35.7k

5.2yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: HQ8F's board of directors are considered experienced (5.2 years average tenure).

This company listing is no longer active

Apollo Endosurgery Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought €206k worth of stock

Apollo Endosurgery, Inc. Announces Board Changes

CEO, President & Director recently sold €432k worth of stock

Recent updates

Full year 2022 earnings released: US$0.98 loss per share (vs US$0.82 loss in FY 2021)

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.23 loss in 3Q 2021)

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Second quarter 2022 earnings released: US$0.26 loss per share (vs US$0.11 loss in 2Q 2021)

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.17 loss in 1Q 2021)

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought €206k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Apollo Endosurgery, Inc. Announces Board Changes

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold €432k worth of stock

Chief Financial Officer recently bought €186k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Insider recently sold €105k worth of stock

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

New 90-day high: €6.05

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Revenue beats expectations

Insider recently bought €70k worth of stock

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought €121k worth of stock

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: €3.76

New 90-day high: €2.00

Revenue beats expectations

Third quarter 2020 earnings released: US$0.11 loss per share

New 90-day high: €1.51

New 90-day low - €1.13

New 90-day low - €1.20

First half earnings released

Apollo Endosurgery, Inc. announced that it expects to receive $25 million in funding

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad